Increased risk of thromboembolic events is associated with prostate cancer, specifically linked to activation of tissue factor. Vitamin D has potential anticoagulant effects by the downregulation of tissue factor expression.
OBJECTIVES:
To evaluate the effects on clot formation, the morphological and viscoelastic profiles of prostate cancer patients, before and after ex vivo supplementation of Vitamin D was studied.
METHODS:
Participants were recruited into a metastatic, non-metastatic and reference group. Whole blood samples were treated ex vivo with a dose of 0.5μg/kg Calcitriol. Clot kinetics were assessed using Thromboelastography®. Morphology of the blood components were studied using scanning electron microscopy (SEM).
RESULTS:
Results from the Thromboelastography® and SEM indicated no major differences between the non-metastatic group before and after treatment compared to the reference group. The Thromboelastography® showed that the metastatic group had an increased viscoelastic profile relating to a hypercoagulable state. Visible changes with regards to platelet activation and fibrin morphology were demonstrated with SEM analysis of the metastatic group. The viscoelastic and morphological properties for the non-metastatic group after treatment improved to be comparable to the reference group.
CONCLUSION:
Vitamin D supplementation may lead to a more favorable viscoelastic profile, with less dangerous clots forming.
TorreLA, SiegelRL, WardEM, JemalA. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiology and Prevention Biomarkers. 2016;25(1):16–27.
2.
Zhen-yuS, QiumingY, ZhiyuanZ, ZheM, GangC. Circulating vitamin D level and mortality in prostate cancer patients: a dose–response meta-analysis. Endocrine Connections. 2018;7(12):R294–R303.
3.
MahalBA, AizerAA, ZiehrDR, HyattAS, ChoueiriTK, HuJC, et al. Racial disparities in prostate cancer–specific mortality in men with low-risk prostate cancer. Clinical Genitourinary Cancer. 2014;12(5):e189–e95.
4.
BostwickDG, BurkeHB, DjakiewD, EulingS, HoSm, LandolphJ, et al. Human prostate cancer risk factors. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2004;101(S10):2371–490.
5.
GuptaD, LammersfeldC, TrukovaK, LisC. Vitamin D and prostate cancer risk: a review of the epidemiological literature. Prostate Cancer and Prostatic Diseases. 2009;12(3):215–26.
6.
LiebmanHA, O’ConnellC. Incidental venous thromboembolic events in 2016. cancer patients: what we know in Thrombosis Research. 2016;140:S18–S20.
7.
GuoQ, HuangB, ZhaoJ, MaY, YuanD, YangY, et al. Perioperative pharmacological thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Annals of Surgery. 2017;265(6):1087–93.
8.
AgnelliG, VersoM. Management of venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis. 2011;9:316–24.
9.
OrdingAG, Horváth-PuhóE, LashTL, EhrensteinV, BorreM, VybergM, et al. Prostate cancer, comorbidity, and the risk of venous thromboembolism: A cohort study of 44,035 Danish prostate cancer patients, 1995-2011. Cancer. 2015;121(20):3692–9.
10.
ToukhM, SiemensDR, BlackA, RobbS, LeveridgeM, GrahamCH, et al. Thromboelastography Identifies Hypercoagulablilty and Predicts Thromboembolic Complications in Patients with Prostate Cancer. Thrombosis Research. 2014;133(1):88–95.
11.
Van HemelrijckM, AdolfssonJ, GarmoH, Bill-AxelsonA, BrattO, IngelssonE, et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. The Lancet Oncology. 2010;11(5):450–8.
12.
ChaturvediS, SidanaS, ElsonP, KhoranaAA, McCraeKR. Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer. PLoS One. 2014;9(8):e94048.
13.
VastoS, CarrubaG, CandoreG, ItalianoE, Di BonaD, CarusoC. Inflammation and prostate cancer. 2008.
14.
ChoA, McKelveyKJ, LeeA, HudsonAL. The intertwined fates of inflammation and coagulation in glioma. Mammalian Genome. 2018;29(11-12):806–16.
15.
TikhomirovaI, PetrochenkoE, MalyshevaY, RyabovM, KislovN. Interrelation of blood coagulation and hemorheology in cancer. Clinical Hemorheology and Microcirculation. 2016;64(4):635–44.
16.
ChuAJ. Tissue factor mediates inflammation. Archives of Biochemistry and Biophysics. 2005;440(2):123–32.
17.
WitkowskiM, LandmesserU, RauchU. Tissue factor as a link between inflammation and coagulation. Trends in Cardiovascular Medicine. 2016;26(4):297–303.
18.
LakshmananRS, EfremovV, O’DonnellJS, KillardAJ. Measurement of the viscoelastic properties of blood plasma clot formation in response to tissue factor concentration-dependent activation. Analytical and Bioanalytical Chemistry. 2016;408(24):6581–8.
19.
AndreasenEB, NielsenOL, TranholmM, KnudsenT, KristensenAT. Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation. Veterinary and Comparative Oncology. 2016;14(2):191–201.
20.
NickelKF, RonquistG, LangerF, LabbertonL, FuchsTA, BokemeyerC, et al. The polyphosphate–factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood, The Journal of the American Society of Hematology. 2015;126(11):1379–89.
21.
BabikerAA, HamadOA, SanchezJ, RonquistG, NilssonB, EkdahlKN. Prothrombotic effect of prostasomes of metastatic cell and seminal origin. The Prostate. 2007;67(4):378–88.
22.
LangerF, ChunFK-H, AmirkhosraviA, FriedrichM, LeuenrothS, EifrigB, et al. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers. Thrombosis and Haemostasis. 2007;97(03):464–70.
23.
HarahshehY, HoKM. Use of viscoelastic tests to predict clinical thromboembolic events: A systematic review and meta-analysis. European Journal of Haematology. 2018;100(2):113–23.
24.
WhitingP, AlM, WestwoodM, RamosIC, RyderS, ArmstrongN, et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. 2015.
25.
HarahshehY, HoK. Viscoelastic point-of-care testing to guide transfusion and antithrombotic therapy in perioperative and critically ill patients: are all parameters created equal? : SAGE Publications Sage UK: London, England; 2016. pp. 11–3.
26.
EhsanianR, TimmermanMA, WrightJM, McKennaS, DirlikovB, CrewJ. Venous Thromboembolism is Associated With Lack of Vitamin D Supplementation in Patients With Spinal Cord Injury and Low Vitamin D Levels. PM&R. 2019;11(2):125–34.
27.
TargherG, PichiriI, LippiG, editors. Vitamin D, thrombosis, and hemostasis: more than skin deep. Seminars in thrombosis and hemostasis; 2012: Thieme Medical Publishers.
28.
FarberPL, DiasA, FreitasT, PinhoAC, ViggianoD, SaldanhaC, et al. Evaluation of hemorheological parameters as biomarkers of calcium metabolism and insulin resistance in postmenopausal women. Clinical Hemorheology and Microcirculation. 2021;77(4):395–410.
29.
BlondonM, BiverE, BraillardO, RighiniM, FontanaP, CasiniA. Thrombin generation and fibrin clot structure after vitamin D supplementation. Endocrine Connections. 2019;8(11):1447–54.
30.
Castillejos-MolinaRA, Gabilondo-NavarroFB. Cáncer de próstata. salud pública de méxico. 2016;58(2):279–84.
31.
AndreasenE, NielsenO, TranholmM, KnudsenT, KristensenA. Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation. Veterinary and Comparative Oncology. 2016;14(2):191–201.
32.
NyameYA, MurphyAB, BowenDK, JordanG, BataiK, DixonM, et al. Associations between serum vitamin D and adverse pathology in men undergoing radical prostatectomy. Journal of Clinical Oncology. 2016;34(12):1345.
33.
WiesingerI, JungF, JungEM. Contrast-enhanced ultrasound (CEUS) and perfusion imaging using VueBox®. Clinical Hemorheology and Microcirculation. 2021;78(1):29–40.
34.
BesterJ, SomaP, KellDB, PretoriusE. Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS). Oncotarget. 2015;6:35284–303.
35.
de VilliersS, SwanepoelA, BesterJ, PretoriusE. Novel Diagnostic and Monitoring Tools in Stroke: an Individualized Patient-Centered Precision Medicine Approach. Journal of Atherosclerosis and Thrombosis. 2015;23:493–504.
36.
PretoriusE, SwanepoelAC, DeVilliersS, BesterJ. Blood clot parameters: Thromboelastography and scanning electron microscopy in research and clinical practice. Thrombosis Research. 2017;154:59–63.
37.
BesterJ, PretoriusE. Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Scientific Reports. 2016;6:32188.
38.
De la FouchardiereC, FlechonA, DrozJ. Coagulopathy in prostate cancer. Neth J Med. 2003;61(11):347–54.
39.
RiihimäkiM, ThomsenH, BrandtA, SundquistJ, HemminkiK. What do prostate cancer patients die of?The Oncologist. 2011;16(2):175.
40.
BluttSE, WeigelNL. Vitamin D and prostate cancer. Proceedings of the Society for Experimental Biology and Medicine. 1999;221(2):89–98.
41.
TrumpDL, Aragon-ChingJB. Vitamin D in prostate cancer. Asian Journal of Andrology. 2018;20(3):244.
42.
ChenTC, HolickMF. Vitamin D and prostate cancer prevention and treatment. Trends in Endocrinology & Metabolism. 2003;14(9):423–30.
43.
SchwartzGG, HulkaB. Is vitamin D deficiency a risk factor for prostate cancer?(Hypothesis). Anticancer Research. 1990;10(5A):1307–11.
44.
SongZ-y, YaoQ, ZhuoZ, MaZ, ChenG. Circulating vitamin d level and mortality in prostate cancer patients: A dose–response meta-analysis. Endocrine Connections. 2018;7(12):R294–R303..
45.
MansonJE, CookNR, LeeI-M, ChristenW, BassukSS, MoraS, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. New England Journal of Medicine. 2019;380(1):33–44.
46.
Klil-DroriAJ, YinH, TagalakisV, AprikianA, AzoulayL. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism. Eur Urol. 2016;70(1):56–61.
47.
ToukhM, SiemensDR, BlackA, RobbS, LeveridgeM, GrahamCH, et al. Thromboelastography identifies hypercoagulablilty and predicts thromboembolic complications in patients with prostate cancer. Thromb Res. 2014;133(1):88–95.
48.
SecinFP, JibornT, BjartellAS, FournierG, SalomonL, AbbouCC, et al. Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol. 2008;53(1):134–45.
49.
EhdaieB, AtoriaCL, GuptaA, FeiferA, LowranceWT, MorrisMJ, et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer. 2012;118(13):3397–406.
50.
Van HemelrijckM, GarmoH, HolmbergL, Bill-AxelsonA, CarlssonS, AkreO, et al. Thromboembolic events following surgery for prostate cancer. Eur Urol. 2013;63(2):354–63.
